English
Regional settings| Spread | 0.50 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ HK$5,000.00 Short position overnight fee ~ HK$4,000.00 | -0.021963% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ HK$5,000.00 Short position overnight fee ~ HK$4,000.00 | 0.000045% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | HKD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Hong Kong | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 20.55 |
| Open | 20.55 |
| 1-Year Change | -18.61% |
| Day's Range | 20.45 - 20.8 |
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd i is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The Company's Great Health segment includes the research, development, manufacturing and sales of beverages, foods, health products and other products. The Company's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The Great Medical segment is engaged in medical services, traditional Chinese medicine health preservation, modern pension and medical equipment industry.
BRIEF: For the fiscal year ended 31 December 2021, Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd revenues increased 12% to RMB69.01B. Net income increased 28% to RMB3.72B. Revenues reflect Business segment increase of 8% to RMB46.89B, Health segment increase of 38% to RMB10.87B, Foreign segment increase of 7% to RMB42.8M. Net income benefited from Change in Fair value decrease from RMB8.5M (expense) to RMB196.9M (income).
